Synthetically Feasible De Novo Molecular Design of Leads Based on a Reinforcement Learning Model: AI-Assisted Discovery of an Anti-IBD Lead Targeting CXCR4
Authors:
- 12 June 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (12) , 10057-10075
Abstract
Artificial intelligence (AI) de novo molecular generation provides leads with novel structures for drug discovery. However, the target affinity and synthesizability of the generated molecules present critical challenges for the successful application of AI technology. Therefore, we developed an advanced reinforcement learning model to bridge the gap between the theory of de novo molecular generation and the practical aspects of drug discovery. This model utilizes chemical reaction templates and commercially available building blocks as a starting point and employs forward reaction prediction to generate molecules, while real-time docking and drug-likeness predictions are conducted to ensure synthesizability and drug-likeness. We applied this model to design active molecules targeting the inflammation-related receptor CXCR4 and successfully prepared them according to the AI-proposed synthetic routes. Several molecules exhibited potent anti-CXCR4 and anti-inflammatory activity in subsequent in vitro and in vivo assays. The top-performing compound XVI alleviated symptoms related to inflammatory bowel disease and showed reasonable pharmacokinetic properties.Keywords
Funding Information
- Hangzhou Normal University (2021QDL026, KYQD-2023-175)
This publication has 41 references indexed in Scilit:
- CXCR4/CXCL12 axis: “old” pathway as “novel” target for anti‐inflammatory drug discoveryMedicinal Research Reviews, 2024
- CXCR4 as possible druggable target linking inflammatory bowel disease and Parkinson's diseaseMetabolic Brain Disease, 2023
- Implications of the changing epidemiology of inflammatory bowel disease in a changing worldUnited European Gastroenterology Journal, 2022
- Bisamide CXCR4 Modulators: Novel Anti‐IBD Agents Acting on the Chemotaxis of Inflammatory CellsAdvanced Therapeutics, 2022
- Pathological roles of the homeostatic chemokine CXCL12Cytokine & Growth Factor Reviews, 2018
- Designing novel building blocks is an overlooked strategy to improve compound qualityDrug Discovery Today, 2015
- CXCL12 Is a constitutive and inflammatory chemokine in the intestinal immune systemInflammatory Bowel Diseases, 2010
- On the Art of Compiling and Using 'Drug‐Like' Chemical Fragment SpacesChemMedChem, 2008
- FlexNovo: Structure‐Based Searching in Large Fragment SpacesChemMedChem, 2006
- LigBuilder: A Multi-Purpose Program for Structure-Based Drug DesignJournal of Molecular Modeling, 2000